Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02973113CT.gov Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoproliferative Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | National Cancer Institute (NCI) | P2 | B · 60 |
| Darbepoetin Alfa | Mayo Clinic | P3 | BB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Fludarabine | Beijing Immunochina Medical Science & Technology Co., Ltd. | P2 | BB |
| Baclofen | Alliance for Clinical Trials in Oncology | P3 | BB |
| Amitriptyline | Alliance for Clinical Trials in Oncology | P3 | BB |
| Tabelecleucel | Pierre Fabre Medicament | P3 | BB |
| Sodium Ferric Gluconate | Mayo Clinic | P3 | BB |
| American Ginseng | Alliance for Clinical Trials in Oncology | P3 | BB |
+40 more in the Lymphoproliferative Syndrome cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Lymphoproliferative Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-lymphoproliferative-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →